Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.2501 ^USD	-6.43%		-18.27%	-41.85%

May. 23	Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment	MT
May. 23	Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation	CI

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004

November 03, 2022 at 08:00 am EDT

Theriva Biologics announced the first patient has been dosed in Cohort 2 of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT)
recipients for the prevention of acute graft-versus-host-disease (aGVHD).

Latest news about Theriva Biologics, Inc.

Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment	May. 23	MT
Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation	May. 23	CI
Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	Apr. 23	CI
Transcript : Theriva Biologics, Inc., 2023 Earnings Call, Mar 25, 2024	Mar. 25
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	Feb. 07	CI
Transcript : Theriva Biologics, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
North American Morning Briefing : Stock Futures -2-	Nov. 13	DJ
Theriva?? Biologics and Sant Joan de Deu-Bar Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer	Nov. 02	CI
Transcript : Theriva Biologics, Inc. - Special Call	23-10-23
Theriva? Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023	23-10-23	CI
Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck	23-10-17	CI
Theriva Biologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Transcript : Theriva Biologics, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Theriva Biologics Announces Key Progress in Virage, an Ongoing, Multinational Phase 2B Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma	23-08-02	CI
Potential US Curbs on AI Chip Exports to China Drag Sentiment, Driving Premarket Losses for US Equity Futures	23-06-28	MT
Top Premarket Gainers	23-06-28	MT
Theriva Gets Orphan Drug Designation for VCN-01 to Treat Pancreatic Cancer	23-06-27	DJ
Theriva Biologics Says US FDA Grants Orphan Drug Designation to VCN-01 for Pancreatic Cancer Treatment; Shares Surge	23-06-27	MT
Theriva Biologics Appoints Ramon Alemany as Senior VP of Discovery	23-05-23	CI
Transcript : Theriva Biologics, Inc., Q1 2023 Earnings Call, May 11, 2023	23-05-11
Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI

Chart Theriva Biologics, Inc.

Duration

Period

More charts

Company Profile

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.2501 USD

Average target price

2 USD

Spread / Average Target

+699.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THERIVA BIOLOGICS, INC.	-41.85%	4.32M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs